KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)

KLOW is a fixed-ratio blend of four research peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic gastric pentadecapeptide), TB-500 (a synthetic fragment of thymosin beta-4), and KPV (the C-terminal tripeptide of alpha-MSH). A common vial format is 80 mg total (50 mg GHK-Cu, 10 mg each of BPC-157, TB-500, and KPV). It is marketed within the peptide community as a combined "repair and recovery" stack rather than as a single characterized drug. The rationale for the combination is mechanistic complementarity: GHK-Cu and TB-500 are associated with extracellular-matrix remodeling and angiogenesis, BPC-157 with cytoprotection and soft-tissue repair signaling, and KPV with dampening NF-kB-driven inflammation. None of these claims for the blend as a whole have been validated in controlled human trials; the supporting data come almost entirely from preclinical (animal and in-vitro) studies of the individual components. KLOW is sold and discussed strictly as a research chemical. None of its components is an FDA-approved drug for human use, and the blend itself has never been studied as a fixed combination in peer-reviewed clinical research. The information here is a research reference, not medical advice or an endorsement of human consumption.